The drug, crenezumab, failed to prevent early symptoms or slow cognitive decline, the latest setback in the long quest to find effective therapies for the disease.
Ook interessant voor je
Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
Almost all children involved with copies of the SMN2 gene treated pre-symptomatically met key milestones
5 x gelezen
What’s next for the synthetic lethality drug discovery engine?
Nature Reviews Drug Discovery, Published online: 16 June 2022; doi:10.1038/d41573-022-00107-0 As a surge of drugs with new synthetic lethality targets enter the clinic, the opportunities and challenges of the underlying...
5 x gelezen
Sanofi and GSK share positive data for two COVID-19 booster vaccine trials
Sanofi and GSK have jointly developed a next-generation COVID-19 booster vaccine candidate, based on Sanofi’s recombinant Beta variant antigen and combined with GSK’s pandemic adjuvant. Both have served as established...
3 x gelezen